Pancreatic cancer has operated by a simple and brutal logic for the better part of four decades: find it late, treat it poorly, bury the patient fast. The five-year survival rate for metastatic disease hovers around 3 percent. The standard second-line chemotherapy regimens that oncologists have been left with — the options handed to patients whose cancer has already progressed once — extend life by a median of roughly six and a half months. That number has barely moved in a generation. Which is what makes the Phase 3 RASolute 302 trial data, presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, so genuinely disorienting.

The drug is daraxonrasib, developed by Revolution Medicines, and in the randomized controlled trial it delivered a median overall survival of 13.2 months against 6.7 months for standard cytotoxic chemotherapy — nearly doubling the time patients stayed alive. The hazard ratio of 0.40, with a p-value well below 0.0001, is not a statistical squint. It is a signal so clean that the trial's plenary presentation was not a quiet footnote at a breakout session. It was a headline slot at the most watched oncology meeting on the planet.

The mechanistic story matters here, because it explains why this took so long and why it matters so much. More than 90 percent of pancreatic cancers carry mutations in the RAS family of oncogenes — primarily KRAS — which lock the cell's growth-signaling machinery into a permanently "on" position, driving uncontrolled proliferation. Scientists identified KRAS as an oncogenic driver in the early 1980s. For decades after that, the protein was classified as "undruggable": its surface offered no obvious pocket for a small molecule to grab onto, and attempts to interrupt it upstream or downstream produced modest gains at enormous toxicity. Daraxonrasib is a RAS(ON) multiselective inhibitor, meaning it targets the active, GTP-bound form of RAS across multiple mutation variants — G12D, G12V, G12R, and others — rather than locking onto a single specific mutation the way earlier, narrower drugs did. That breadth is exactly why the trial enrolled patients across the full spectrum of RAS G12 variants and still produced consistent results.

The efficacy picture is not limited to overall survival. Progression-free survival — the time before the cancer advances — was 7.3 months in the RAS G12 primary analysis population versus 3.5 months on chemotherapy, more than doubling the time patients lived without disease progression. In the broader intent-to-treat population, the OS figure was 13.2 months compared to 6.7 months with chemotherapy, with a hazard ratio of 0.40. The data published concurrently in the New England Journal of Medicine reported a median duration of response of 8.2 months among responders in earlier-phase work, which the Phase 3 results now reinforce at scale.

Then there is the safety data, which in oncology is often where the asterisks pile up. Daraxonrasib's most common treatment-related adverse events were rash, diarrhea, and nausea — predominantly low-grade. Grade 3 or higher treatment-related adverse events occurred in 43.6 percent of daraxonrasib patients, compared with 57.5 percent in the chemotherapy arm. That is not a trivial detail. It means the drug that dramatically outperformed chemotherapy on survival also produced serious side effects at a meaningfully lower rate than the standard of care it replaced. No grade 5 treatment-related events were reported at the 300 mg once-daily dose used in the trial.

The FDA's posture on this has been unusually aggressive by its own standards. After Revolution Medicines filed for an expanded access protocol, the agency issued a "safe to proceed" letter within two days of receiving the application — a timeline the FDA itself described as reflecting its "strong commitment to facilitate early access to therapies for serious and life-threatening conditions." As of late May 2026, the company was actively shipping daraxonrasib under that protocol. The drug does not yet have formal approval, and formal review timelines have not been publicly announced, but expanded access means dying patients can receive it now, before the regulatory machinery completes its full cycle.

What the trial does not resolve is the question of durability and what comes next. Thirteen months is a real improvement over six. It is not a cure. The median follow-up data are still maturing, the upper bound of the survival curve for daraxonrasib recipients had not yet been reached at the data cutoff, and Revolution Medicines has an active Phase 3 trial — RASolute 303 — evaluating the drug in the first-line setting, where patients have not yet failed a prior regimen and where the baseline survival picture is somewhat better. Whether the same magnitude of benefit holds in that context, and whether combinations with chemotherapy or immunotherapy extend it further, are the open questions that will define the next chapter.

The institutional consensus word being used is "gamechanger." In oncology, that word gets deployed loosely and often prematurely. Here the numbers warrant it — with the caveat that a doubling of survival in a disease with a median OS measured in single digits is still, in absolute terms, a fight against a very hard clock. The drug does not cure pancreatic cancer. It gives patients more time, with less suffering from treatment, than anything that came before it. For a disease that has taken roughly 50,000 American lives per year and resisted every serious pharmaceutical advance for four decades, that is not nothing. That is, by the evidence available, the most meaningful forward step the field has ever recorded.